U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H17F3N2O4S
Molecular Weight 426.4113
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FEVIPIPRANT

SMILES

Cc1c(CC(=O)O)c2cccnc2n1Cc3ccc(cc3C(F)(F)F)S(=O)(=O)C

InChI

InChIKey=GFPPXZDRVCSVNR-UHFFFAOYSA-N
InChI=1S/C19H17F3N2O4S/c1-11-15(9-17(25)26)14-4-3-7-23-18(14)24(11)10-12-5-6-13(29(2,27)28)8-16(12)19(20,21)22/h3-8H,9-10H2,1-2H3,(H,25,26)

HIDE SMILES / InChI

Molecular Formula C19H17F3N2O4S
Molecular Weight 426.4113
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Fevipiprant is a selective reversible antagonist of the prostaglandin D2 receptor (also known as CRTH2). It is currently in development for the treatment of allergic diseases.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q9Y5Y4
Gene ID: 11251.0
Gene Symbol: PTGDR2
Target Organism: Homo sapiens (Human)
1.1 nM [Kd]
PubMed

PubMed

TitleDatePubMed
The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma.
2016 Aug
Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers.
2016 Jul
Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy.
2016 May
An evaluation of fevipiprant for the treatment of asthma: a promising new therapy?
2018 Dec
Fevipiprant, a selective prostaglandin D(2) receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function.
2019 Jun
Patents

Sample Use Guides

500 mg once daily.
Route of Administration: Oral
Fevipiprant (QAW039) is currently in development for the treatment of allergic diseases. [3H]-QAW039 displayed high affinity for the human CRTh2 receptor (1.14 +/- 0.44 nM) expressed in Chinese hamster ovary cells, the binding being reversible and competitive with the native agonist prostaglandin D2.
Substance Class Chemical
Created
by admin
on Sat Jun 26 12:50:13 UTC 2021
Edited
by admin
on Sat Jun 26 12:50:13 UTC 2021
Record UNII
2PEX5N7DQ4
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FEVIPIPRANT
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
FEVIPIPRANT [USAN]
Common Name English
2-(1-((4-METHANESULFONYL-2-(TRIFLUOROMETHYL)PHENYL)METHYL(-2-METHYL-1H-PYRROLO(2,3-B)PYRIDIN-3-YL)ACETIC ACID
Common Name English
FEVIPIPRANT [WHO-DD]
Common Name English
QAW039
Code English
NVP-QAW039
Code English
QAW-039
Code English
(1-(4-((METHANE)SULFONYL)-2-TRIFLUOROMETHYLBENZYL)-2-METHYL-1H-PYRROLO(2,3-B)PYRIDIN-3-YL)ACETIC ACID
Common Name English
FEVIPIPRANT [INN]
Common Name English
Code System Code Type Description
DRUG BANK
DB12011
Created by admin on Sat Jun 26 12:50:13 UTC 2021 , Edited by admin on Sat Jun 26 12:50:13 UTC 2021
PRIMARY
NCI_THESAURUS
C166588
Created by admin on Sat Jun 26 12:50:13 UTC 2021 , Edited by admin on Sat Jun 26 12:50:13 UTC 2021
PRIMARY
CAS
872365-14-5
Created by admin on Sat Jun 26 12:50:13 UTC 2021 , Edited by admin on Sat Jun 26 12:50:13 UTC 2021
PRIMARY
ChEMBL
CHEMBL3137332
Created by admin on Sat Jun 26 12:50:13 UTC 2021 , Edited by admin on Sat Jun 26 12:50:13 UTC 2021
PRIMARY
INN
9682
Created by admin on Sat Jun 26 12:50:13 UTC 2021 , Edited by admin on Sat Jun 26 12:50:13 UTC 2021
PRIMARY
FDA UNII
2PEX5N7DQ4
Created by admin on Sat Jun 26 12:50:13 UTC 2021 , Edited by admin on Sat Jun 26 12:50:13 UTC 2021
PRIMARY
PUBCHEM
23582412
Created by admin on Sat Jun 26 12:50:13 UTC 2021 , Edited by admin on Sat Jun 26 12:50:13 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
EXCRETED UNCHANGED
URINE
TRANSPORTER -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
EXCRETED UNCHANGED
FECAL
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC ORAL ADMINISTRATION

SINGLE DOSE

Tmax PHARMACOKINETIC ORAL ADMINISTRATION

SINGLE DOSE